MX2023002468A - Sales, cristales y cocristales novedosos. - Google Patents
Sales, cristales y cocristales novedosos.Info
- Publication number
- MX2023002468A MX2023002468A MX2023002468A MX2023002468A MX2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A MX 2023002468 A MX2023002468 A MX 2023002468A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- crystals
- novel salts
- receptor
- sert
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical compound C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 abstract 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
- C07B63/02—Purification; Separation; Stabilisation; Use of additives by treatment giving rise to a chemical modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075019P | 2020-09-04 | 2020-09-04 | |
| PCT/US2021/071366 WO2022051770A2 (en) | 2020-09-04 | 2021-09-03 | Novel salts, crystals, and co-crystals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002468A true MX2023002468A (es) | 2023-03-23 |
Family
ID=80492079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002468A MX2023002468A (es) | 2020-09-04 | 2021-09-03 | Sales, cristales y cocristales novedosos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230312573A1 (https=) |
| EP (1) | EP4208434A4 (https=) |
| JP (1) | JP2023540506A (https=) |
| KR (1) | KR20230104121A (https=) |
| CN (1) | CN116113622A (https=) |
| AU (1) | AU2021338439A1 (https=) |
| CA (1) | CA3186537A1 (https=) |
| IL (1) | IL300886A (https=) |
| MX (1) | MX2023002468A (https=) |
| WO (1) | WO2022051770A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268970B2 (en) | 2017-03-24 | 2023-12-01 | Intra Cellular Therapies Inc | Oral transmucosal formulations of substituted heterocycle fused gamma carbolines |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| WO2025240804A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices and methods |
| CN118566395B (zh) * | 2024-08-02 | 2024-10-25 | 则正(济南)生物科技有限公司 | 测定甲苯磺酸卢美哌隆口崩片中杂质含量的方法、应用和系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3407889T3 (pl) * | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego |
| US11014925B2 (en) * | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| IL268970B2 (en) * | 2017-03-24 | 2023-12-01 | Intra Cellular Therapies Inc | Oral transmucosal formulations of substituted heterocycle fused gamma carbolines |
| JP2020513023A (ja) * | 2017-04-10 | 2020-04-30 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ルマテペロンｐ−トシラートの非晶質形態および固体分散体 |
| CN111107847A (zh) * | 2017-09-26 | 2020-05-05 | 细胞内治疗公司 | 新的盐和晶体 |
| IL321985A (en) * | 2018-06-06 | 2025-09-01 | Intra Cellular Therapies Inc | New salts and crystals |
| CA3106447A1 (en) * | 2018-06-11 | 2019-12-19 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| EP3843729A4 (en) * | 2018-08-29 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND PROCESSES |
| US20220024924A1 (en) * | 2018-11-27 | 2022-01-27 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
| JP7673040B2 (ja) * | 2019-07-07 | 2025-05-08 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| EP4034119A4 (en) * | 2019-09-25 | 2023-10-18 | Intra-Cellular Therapies, Inc. | NOVEL METHODS |
-
2021
- 2021-09-03 WO PCT/US2021/071366 patent/WO2022051770A2/en not_active Ceased
- 2021-09-03 IL IL300886A patent/IL300886A/en unknown
- 2021-09-03 CA CA3186537A patent/CA3186537A1/en active Pending
- 2021-09-03 JP JP2023514771A patent/JP2023540506A/ja active Pending
- 2021-09-03 US US18/043,959 patent/US20230312573A1/en active Pending
- 2021-09-03 MX MX2023002468A patent/MX2023002468A/es unknown
- 2021-09-03 CN CN202180054461.5A patent/CN116113622A/zh active Pending
- 2021-09-03 KR KR1020237010822A patent/KR20230104121A/ko active Pending
- 2021-09-03 EP EP21865304.6A patent/EP4208434A4/en active Pending
- 2021-09-03 AU AU2021338439A patent/AU2021338439A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116113622A (zh) | 2023-05-12 |
| KR20230104121A (ko) | 2023-07-07 |
| WO2022051770A2 (en) | 2022-03-10 |
| IL300886A (en) | 2023-04-01 |
| WO2022051770A3 (en) | 2022-04-14 |
| AU2021338439A1 (en) | 2023-02-23 |
| EP4208434A2 (en) | 2023-07-12 |
| JP2023540506A (ja) | 2023-09-25 |
| CA3186537A1 (en) | 2022-03-10 |
| EP4208434A4 (en) | 2024-10-16 |
| US20230312573A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002468A (es) | Sales, cristales y cocristales novedosos. | |
| Kiss et al. | Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist–partial agonist antipsychotic candidate: in vitro and neurochemical profile | |
| JP2019513143A5 (https=) | ||
| MX2022007105A (es) | Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico. | |
| BR112019019928A2 (pt) | derivados de indolina substituídos como inibidores da replicação viral da dengue | |
| MX2020009928A (es) | Compuestos organicos. | |
| JP2014525470A5 (https=) | ||
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| RU2006135652A (ru) | Производные индол-1-илуксусной кислоты | |
| NO20074781L (no) | 4-Oksokinazolin-3-ylbenzamidderivater for behandling av cytokinsykdommer | |
| AR062111A1 (es) | Derivados de beta-d-glucopiranosil indol, metodo de preparacion, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
| BR112019020175A2 (pt) | Derivados de indolina substituídos como inibidores da replicação viral da dengue | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| UA125296C2 (uk) | Заміщені похідні індоліну як інгібітори реплікації вірусів денге | |
| MX2020012978A (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| CR20200355A (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| WO2023178111A3 (en) | Organic compounds | |
| ECSP21018584A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| JP2018530608A5 (https=) | ||
| EA202091773A1 (ru) | Способ модуляции сигнальных путей tigit и pd-1 с применением 1,2,4-оксадиазольных соединений | |
| EA202092146A1 (ru) | Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора | |
| JP6877359B2 (ja) | イミダゾール誘導体 | |
| PE20080191A1 (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 |